Evaluating the Evidence for CYP2C19 Inhibitor Classifications: A Scoping Review
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3712 ↗Kurz gefasst
Scoping Review in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Jean G Malavé und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of F…. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C19, Cytochrome P-450 CYP2C19 Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Abstract (Originalsprache)
The Food and Drug Administration (FDA) Table of Inhibitors and the Flockhart Table™ are important references for identifying CYP2C19 inhibitors. Accurate inhibitor classification is essential for evaluating phenoconversion and managing drug–drug interactions. The objective of this study was to assess the concordance between inhibitor classifications according to the FDA and Flockhart tables and pharmacokinetic data from the primary literature. A scoping review of PubMed, product labels, and the Drug Interactions Database (DIDB®) up to April 2024 was conducted. Inhibitor‐substrate pairs (e.g., fluoxetine‐omeprazole) were assigned literature‐reported classifications (i.e., weak, moderate, or strong) based on pharmacokinetic data. Concordance between literature‐reported and listed classifications was evaluated. Of 90 inhibitor‐substrate pairs identified, 66% involved sensitive substrates, which were the focus of our primary analysis. Among sensitive inhibitor‐substrate pairs, 36% of FDA‐listed and 45% of Flockhart‐listed classifications were concordant with the literature. CYP2C19 phenotype appeared to impact concordance, with greater concordance among normal metabolizers for both FDA‐listed (42%) and Flockhart‐listed (50%) classifications. Steady state status and dosing also appeared to affect concordance. Discrepancies between listed and literature‐reported classifications led to the following recommendations: (1) upgrade fluoxetine from moderate to strong in the Flockhart Table™, (2) upgrade fluconazole from moderate to strong in the Flockhart Table™, (3) downgrade omeprazole (and esomeprazole) from moderate to weak in the Flockhart Table™, and (4) include footnotes describing dose‐dependent inhibition for fluvoxamine and fluconazole in both tables. These recommendations aim to improve the accuracy of CYP2C19 inhibitor classifications and the clinical utility of these tables.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
- Division of Clinical Pharmacology, Indiana University, School of Medicine, Indianapolis, Indiana, USA.
ORCID-Profile: Jean G Malavé, Emily J Cicali, Larisa H Cavallari
Zitieren
APA
Malavé, J. G., Lopez, A., Doan, T., Cicali, E. J., Desta, Z., McDonough, C. W., & Cavallari, L. H. (2025). Evaluating the Evidence for CYP2C19 Inhibitor Classifications: A Scoping Review. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3712
Vancouver
Malavé JG, Lopez A, Doan T, Cicali EJ, Desta Z, McDonough CW, et al. Evaluating the Evidence for CYP2C19 Inhibitor Classifications: A Scoping Review. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3712
BibTeX
@article{Malav2025,
author = {Malavé, Jean G and Lopez, Andrés and Doan, Thi and Cicali, Emily J and Desta, Zeruesenay and McDonough, Caitrin W and Cavallari, Larisa H},
title = {Evaluating the Evidence for CYP2C19 Inhibitor Classifications: A Scoping Review},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3712}
}
EUVIMED